Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aevi Genomic Medicine Inc.

www.aevigenomics.com

Latest From Aevi Genomic Medicine Inc.

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo

Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.

Deals Business Strategies

Supernus’ ADHD Drug Hits Phase III Endpoint As Filing Beckons

The first of two Phase III trials of Supernus’ ADHD candidate has hit its endpoints in adolescents. The second is due to report in early 2019, setting the stage for regulatory filings.

Clinical Trials Research & Development

Amicus Makes Its Gene Therapy Move, Focusing On CNS Lysosomal Storage Disorders

The rare disease specialist gained 10 gene therapy programs with the acquisition of Celenex, including two in clinical-stage development for Batten disease, in exchange for $100m up front. President Bradley Campbell talked to Scrip about the process that led to the deal and next steps for development.

Deals Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Gastrointestinal
  • Immune Disorders
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Medgenics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aevi Genomic Medicine Inc.
  • Senior Management
  • Michael F Cola, Pres. & CEO
    Michael H McInaw, CFO
    Garry A Neil, MD, CSO
  • Contact Info
  • Aevi Genomic Medicine Inc.
    Phone: (610) 254-4201
    435 Devon Park Dr., Ste. 715
    Wayne, PA 19087
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register